Fab that binds to dabigatran and its acylglucuronide metabolites with higher affinity than the binding affinity of dabigatran to thrombin, neutralizing their anticoagulant effects
Idarucizumab
Tocilizumab
Sotrovimab
Obiltoxaximab
Sarilumab
Raxibacumab
Rituximab
Baricitinib